top of page

Alnylam's CEO Dr. Yvonne Greenstreet discusses HELIOS-B at the European Society of Cardiology Congress in London

  • blonca9
  • Aug 31, 2024
  • 1 min read

Dr. Greenstreet shares her opinion of why she believes the data places vutrisiran in a competitive position to be a first line choice for ATTR-CM, and clarifies market confusion around a data point that was presented yesterday.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

KH_Logo_Horizontal_Tagline_Black-1.png

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

bottom of page